{"id":"celebrex-plus-metformin","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Lactic acidosis risk (metformin)"},{"rate":null,"effect":"Cardiovascular events (celecoxib)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin-mediated inflammation without affecting COX-1-dependent gastric protection. Metformin decreases hepatic glucose production and increases peripheral insulin sensitivity, lowering blood glucose levels. The combination may address both inflammatory and metabolic components of disease.","oneSentence":"This combination uses celecoxib (a COX-2 inhibitor) to reduce inflammation and metformin (a biguanide) to improve insulin sensitivity and glucose metabolism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:11.146Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes with inflammatory comorbidities (Phase 3 investigational)"}]},"trialDetails":[{"nctId":"NCT07139405","phase":"PHASE2","title":"TRIGLYTZA® VERSUS METFORMIN IN OBESE ADULT TYPE 2 DIABETES (T2DM) PATIENTS OVER 24 WEEKS OF TREATMENT","status":"NOT_YET_RECRUITING","sponsor":"Myopharm Limited","startDate":"2026-02","conditions":"Type 2 Diabetes (T2DM)","enrollment":90},{"nctId":"NCT03686657","phase":"PHASE1, PHASE2","title":"Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients","status":"NOT_YET_RECRUITING","sponsor":"ARKAY Therapeutics","startDate":"2025-10-10","conditions":"Type 2 Diabetes, High Blood Pressure, Arthritis","enrollment":115},{"nctId":"NCT00268476","phase":"PHASE2, PHASE3","title":"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical Research Council","startDate":"2005-07-08","conditions":"Prostate Cancer","enrollment":11992},{"nctId":"NCT03184493","phase":"PHASE3","title":"Celebrex and Metformin for Postoperative Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2017-06-02","conditions":"Liver Cancer","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Celebrex plus Metformin","genericName":"Celebrex plus Metformin","companyName":"Guangxi Medical University","companyId":"guangxi-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses celecoxib (a COX-2 inhibitor) to reduce inflammation and metformin (a biguanide) to improve insulin sensitivity and glucose metabolism. Used for Type 2 diabetes with inflammatory comorbidities (Phase 3 investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}